Shopping Cart
Remove All
Your shopping cart is currently empty
Synonyms: DI03


| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 5 mg | $70 | In Stock | In Stock | |
| 10 mg | $128 | In Stock | In Stock | |
| 25 mg | $263 | In Stock | In Stock | |
| 50 mg | $392 | In Stock | In Stock | |
| 100 mg | $575 | In Stock | In Stock | |
| 200 mg | $818 | In Stock | - | |
| 1 mL x 10 mM (in DMSO) | $77 | In Stock | In Stock |
| Description | D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 µM. D-I03 inhibits RAD52-dependent single-strand annealing (SSA) and D-loop formation, with IC₅₀ values of 5 µM and 8 µM, respectively. D-I03 exerts significant growth inhibition on BRCA1/2-deficient cancer cells but has no effect on RAD51. D-I03 can be used in combination therapy studies for tumors with DNA damage repair defects. |
| Targets & IC50 | RAD52:25.8 µM (Ki), single-chain annealing (SSA):5 µM, D-loop:8 µM |
| In vitro | Methods: In BRCA1-mutant UWB1.298 and MDA-MB-436 cells, medium containing different concentrations of D-I03 (0 μM, 2.5 μM, 5 μM, and 10 μM) was added on days 1 and 3, respectively. On day 4, cells were harvested and viable cells were counted using the trypan blue exclusion Methods. An equal number of viable cells were then subcultured into fresh 6-well plates and cultured in drug-free normal medium for approximately 2 weeks to allow single cells to proliferate and form colonies. Results: D-I03 significantly inhibited colony formation in a dose-dependent manner within the concentration range of 2.5–10 μM.[1] |
| In vivo | Methods: Using a BRCA2-deficient, PARP inhibitor-resistant ovarian cancer C57BL/6 mouse model, mice received olaparib (75 mg/kg, oral infusion), D-I03 (25 mg/kg, intraperitoneal injection), olaparib plus D-I03, or vehicle treatment for 20 days. Results: Combination therapy with D-I03 and PARP inhibitors reduced tumor burden and prolonged survival.[2] |
| Synonyms | DI03 |
| Molecular Weight | 428.64 |
| Formula | C23H36N6S |
| Cas No. | 688342-78-1 |
| Smiles | CCN(CC)CCNC(=S)Nc1ccc2nc(cc(C)c2c1)N1CCN(CC)CC1 |
| Relative Density. | 1.147 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 90 mg/mL (209.97 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (7.7 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density. | ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 µL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 µL Tween 80 and mix well until fully clarified.
3) Add 450 µL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.